| Literature DB >> 33052140 |
Yunfei Liao1, Yong Feng2, Bo Wang3, Hanyu Wang1, Jinsha Huang4, Yaxin Wu5, Ziling Wu1, Xiao Chen1, Chao Yang6, Xinqiao Fu7, Hui Sun1.
Abstract
The outbreak of coronavirus disease 2019 (COVID-19) has become a world-wide emergency. The severity of COVID-19 is highly correlated with its mortality rate. We aimed to disclose the clinical characteristics and prognostic factors of COVID-19 patients who developed severe COVID-19. The study enrolled cases (no=1848) with mild or moderate type of COVID-19 in Fangcang shelter hospital of Jianghan. A total of 56 patients progressed from mild or moderate to severe. We used least absolute shrinkage and selection operator regression model to select prognostic factors for this model. The case-severity rate was 3.6% in the shelter hospital. They were all symptomatic at admission. Fever, cough, and fatigue were the most common symptoms. Hypertension, diabetes and coronary heart diseases were common co-morbidities. Predictors contained in the prediction nomogram included fever, distribution of peak temperature (>38°C), myalgia or arthralgia and distribution of C-reactive protein (≥10 mg per L). The distribution of peak temperature (>38°C) on set, myalgia or arthralgia and C-reactive protein (≥10 mg per L) were the prognostic factors to identify the progression of COVID-19 patients with mild or moderate type. Early attention to these risk factors will help alleviate the progress of the COVID-19.Entities:
Keywords: COVID-19; clinical characteristics; nomogram; prognostic factors
Year: 2020 PMID: 33052140 PMCID: PMC7732300 DOI: 10.18632/aging.103931
Source DB: PubMed Journal: Aging (Albany NY) ISSN: 1945-4589 Impact factor: 5.682
Figure 1Outcome and distribution of all enrolled patients in Jianghan Fangcang shelter hospital (1848).
Clinical characteristics of patients transferring to the designated hospitals from fangcang shelter hospital.
| Age | 55 (48-61) | 52 (44-58) | 62 (52-64) | 54 (48-62) | 53 (45-61) |
| Female sex | 26(46.4%) | 22 (61.1%) | 58 (74.4%) | 47 (42.0%) | 132 (55.2%) |
| Median incubation (onset to cabin) period | 10 (8-16) | 12 (6-13) | 12 (10-23) | 12 (7-18) | 13 (9-19) |
| Median cabin period | 4 (3-8) | 7 (4-12) | 17 (13-22) | 16 (12-21) | 18 (14-22) |
| Median incubation (onset to transfer) period | 15 (12-23) | 20 (11-25) | 30 (29-37) | 19 (17-26) | 31 (25-37) |
| Fever on cabin admission | |||||
| Patients | 43(76.8%) | 24 (67.7%) | 16 (20.5%) | 52 (46.4%) | 88 (36.8%) |
| Median temperature (of peak value) | 38.2±0.71 | 38.8±0.47 | 38.1±0.39 | 38.2±0.68 | 38.2±0.53 |
| Symptoms at onset | |||||
| Cough | 34 (60.7%) | 18 (50.0%) | 33 (42.3%) | 50 (44.6%) | 88 (36.8%) |
| Sputum production | 3 (5.4%) | 1 (2.8%) | 5 (6.4%) | 8 (7.1%) | 15 (6.3%) |
| Nasal congestion | 4 (7.1%) | 1 (2.8%) | 3 (3.8%) | 9 (8.0%) | 13 (5.4%) |
| Sore throat | 11(19.6%) | 6 (16.7%) | 10 (12.8%) | 14 (12.5%) | 31 (13.0%) |
| Shortness of breath | 10(17.9%) | 6 (16.7%) | 10 (12.8%) | 16 (14.3%) | 29 (12.1%) |
| Stomach ache | 1(1.8%) | 0 | 1 (1.3%) | 2 (1.8%) | 5 (2.1%) |
| Chest pain | 5 (8.9%) | 3 (8.3%) | 6 (7.7%) | 8 (7.1%) | 17 (7.1%) |
| Chest congestion | 10(17.9%) | 3 (8.3%) | 8 (10.3%) | 13 (11.6%) | 32 (13.4%) |
| Nausea or vomiting | 4 (7.1%) | 1 (2.8%) | 5 (6.4%) | 7 (6.3%) | 10 (4.2%) |
| Diarrhea | 11(19.6%) | 5 (13.9%) | 20 (12.8%) | 18 (16.1%) | 16 (6.7%) |
| Myalgia or arthralgia | 17 (30.4%) | 9 (25.0%) | 18 (25.6%) | 30 (26.8%) | 60 (25.1%) |
| Poor appetite | 16 (28.6%) | 9 (25.0%) | 17 (21.8%) | 27 (24.1%) | 57 (23.8%) |
| Headache | 2 (3.6%) | 2 (5.6%) | 2 (2.6%) | 3 (2.7%) | 11 (4.6%) |
| Fatigue | 32 (57.1%) | 20 (55.6%) | 37 (47.4%) | 52 (46.4%) | 71 (29.7%) |
| Chills | 5 (8.9%) | 3 (8.3%) | 4 (5.1%) | 8 (7.1%) | 18 (7.5%) |
| Palmic | 2 (3.6%) | 1 (2.8%) | 1 (1.3%) | 2 (1.8%) | 10 (4.2%) |
| Perspire | 1(1.8%) | 0 | 1 (1.3%) | 1 (0.9%) | 3 (1.3%) |
| Comorbidity | |||||
| Any | 23 (41.1%) | 14 (38.9%) | 78 (100%) | 49 (43.8%) | 82 (34.3%) |
| Chronic obstructive pulmonary disease | 1 (1.8%) | 1 (2.8%) | 10 (12.8%) | 2 (1.8%) | 6 (2.5%) |
| Diabetes | 4 (7.1%) | 2 (5.6%) | 16 (20.5%) | 8 (7.1%) | 13 (5.4%) |
| Hypertension | 13 (23.2%) | 7 (19.4%) | 25 (32.1%) | 27 (24.1%) | 45 (18.8%) |
| Coronary heart disease | 4 (7.1%) | 2 (5.6%) | 9 (11.5%) | 8 (7.1%) | 11 (5.3%) |
| Cerebrovascular disease | 1 (1.8%) | 1 (2.8%) | 9 (11.5%) | 2 (1.8%) | 4 (1.7%) |
| Chronic renal disease | 1 (1.8%) | 0 | 9 (11.5%) | 2 (1.8%) | 3 (1.3%) |
Data are median (IQR), n (%) or n/N (%).
Clinical characteristics of the mild or moderate progressed to severe patients.
| Age | |||
| Median (IQR) — year | 55 (48-61) | 56 (48-62) | 0.909 |
| Distribution of age— no./total no. (%) | .. | .. | 0.976 |
| <40 | 7 (12.5%) | 11 (12.0%) | .. |
| 40-65 | 43 (76.8%) | 72 (78.3%) | .. |
| >65 | 6 (10.7%) | 9 (9.8%) | .. |
| Female sex — no./total no. (%) | 26(46.4%) | 48 (52.2%) | 0.498 |
| Smoking history — no./total no. (%) | 3 (5.4%) | 5 (5.4%) | 0.984 |
| Median incubation (onset to shelter) period (IQR) — days | 10 (8-16) | 14 (11-19) | <0.0001 |
| Distribution of period— no./total no. (%) | .. | .. | 0.016* |
| <7days | 7(12.5%) | 9 (9.8%) | .. |
| 7-14days | 34 (60.7%) | 36 (39.1%) | .. |
| >14days | 14 (25.0%) | 44 (47.8%) | .. |
| Median cabin period (IQR) — days | 4 (3-8) | 17 (12-22) | <0.0001 |
| Distribution of period — no./total no. (%) | .. | .. | <0.0001* |
| <3days | 12 (21.8%) | 1 (1.1%) | .. |
| 3-7days | 29(52.7%) | 10 (11.0%) | .. |
| >7days | 14 (25.5%) | 80 (87.9%) | .. |
| Median incubation (onset to transfer) period (IQR) — days | 15 (12-23) | 33 (28.5-37) | <0.0001 |
| Distribution of period — no./total no. (%) | .. | .. | <0.0001* |
| <7days | 2 (3.6%) | 0 | .. |
| 7-14days | 24 (43.6%) | 2 (2.2%) | .. |
| >14days | 29 (52.7%) | 87 (97.8%) | .. |
| Fever on cabin admission | |||
| Patients — no./total no. (%) | 43(76.8%) | 24 (26.1%) | <0.0001 |
| Mean temperature (of peak value) (SDs)— °C | 38.2±0.71 | 37.7±0.58 | 0.011 |
| Distribution of peak temperature — no./total no. (%) | .. | .. | 0.046* |
| <37.3°C | 4 (7.1%) | 22 (23.9%) | .. |
| 37.3–38.0°C | 21(37.5%) | 54 (58.7%) | .. |
| 38.1–39.0°C | 24(42.9%) | 16 (17.4%) | .. |
| >39.0°C | 7 (12.5%) | 0 | .. |
| Symptoms at onset — no. (%) | |||
| Cough | 34 (60.7%) | 36 (39.1%) | 0.011 |
| Sputum production | 3 (5.4%) | 11 (12.0%) | 0.183 |
| Nasal congestion | 4 (7.1%) | 2(2.2%) | 0.137 |
| Sore throat | 11(19.6%) | 4(4.4%) | 0.003 |
| Shortness of breath | 10(17.9%) | 4(4.4%) | 0.006 |
| Stomach ache | 1(1.8%) | 2(2.2%) | 0.871 |
| Chest pain | 5 (8.9%) | 3(3.3%) | 0.139 |
| Chest congestion | 10(17.9%) | 13(14.1%) | 0.544 |
| Nausea or vomiting | 4 (7.1%) | 3(3.3%) | 0.281 |
| Diarrhea | 11(19.6%) | 7(7.6%) | 0.03 |
| Myalgia or arthralgia | 17 (30.4%) | 6(6.5%) | <0.0001 |
| poor appetite | 16 (28.6%) | 6(6.5%) | <0.0001 |
| Headache | 2 (3.6%) | 7(7.6%) | 0.319 |
| Fatigue | 32 (57.1%) | 25(27.2%) | <0.0001 |
| Chills | 5 (8.9%) | 5(5.4%) | 0.412 |
| Palmic | 2 (3.6%) | 6(6.5%) | 0.441 |
| Perspire | 1(1.8%) | 0 | 0.198 |
| Cough | 34 (60.7%) | 36 (39.1%) | 0.011 |
| Sputum production | 3 (5.4%) | 11 (12.0%) | 0.183 |
| Comorbidity — no. (%) | |||
| Any | 24 (42.9%) | 28 (30.4%) | 0.187 |
| Chronic obstructive pulmonary disease | 1 (1.8%) | 2 (2.2%) | 0.871 |
| Diabetes | 4 (7.1%) | 3 (3.3%) | 0.281 |
| Hypertension | 13 (23.2%) | 17 (18.5%) | 0.487 |
| Coronary heart disease | 4 (7.1%) | 3 (3.3%) | 0.281 |
| Cerebrovascular disease | 1 (1.8%) | 3 (3.3%) | 0.591 |
| Chronic renal disease | 1 (1.8%) | 0 | 0.198 |
Data are mean (SDs), median (IQR), n (%), or n/N (%). P values were calculated by Student t test, Mann-Whitney U test, χ² test, or Fisher’s exact test, as appropriate. *χ² test comparing all subcategories.
Radiographic, laboratory findings, treatments, and clinical outcomes.
| Abnormalities on chest CT — no./total no. (%) | |||
| Local | 22 (39.3%) | 10 (10.9%) | <0.0001 |
| Multiple | 11 (19.6%) | 52 (56.5%) | <0.0001 |
| Bilateral | 24 (42.9%) | 72 (78.3%) | <0.0001 |
| Unilateral | 7 (12.5%) | 18 (19.6%) | 0.374 |
| Patchy shadowing | 10 (17.9%) | 7 (7.6%) | 0.034 |
| Ground-glass opacity | 53 (94.6%) | 82 (89.1%) | 0.432 |
| Interstitial abnormalities | 1 (1.8%) | 19 (20.7%) | 0.002 |
| Laboratory findings | |||
| White-cell count, median (IQR), × 109 per L | 5.75(4.66 -7.91) | 5.96 (5.04-7.09) | 0.848 |
| Lymphocyte count, mean (SDs), × 109 per L | 1.70±0.72 | 1.88±0.54 | 0.244 |
| Distribution of lymphocyte count— no./total no. (%) | 42 | 90 | 0.468 |
| <1.5× 109 per L | 15 (35.7%) | 24 (26.7%) | .. |
| ≥1.5 × 109 per L | 27 (64.3%) | 66 (73.3%) | .. |
| Platelet count, median (IQR), × 109 per L | 238 (181-331) | 244 (205-320) | 0.724 |
| Distribution of platelet count— no./total no. (%) | 42 | 90 | 0.183 |
| <150 × 109 per L | 2 (4.8%) | 1 (1.1%) | .. |
| ≥150 × 109 per L | 40 (95.2%) | 89 (98.9%) | .. |
| Median hemoglobin (IQR) — g per dl | 134 (131-147) | 137 (128-144) | 0.828 |
| C-reactive protein, median (IQR), mg per L | 10.12 (1.33-16.44) | 1.14 (0.37-2.61) | <0.0001 |
| Distribution — no./total no. (%) | 42 | 90 | <0.0001* |
| C-reactive protein ≥10 mg per L | 14 (33.3%) | 5 (5.6%) | .. |
| C-reactive protein <10 mg per L | 28 (66.7%) | 85 (94.4%) | .. |
| 42 | 90 | .. | |
| Antibiotics, antivirus and traditional Chinese medicine | 16 (38.1%) | 40 (50.6%) | 0.188 |
| Antibiotics and antivirus | 5 (11.9%) | 3 (3.9%) | 0.091 |
| Antivirus and traditional Chinese medicine | 6 (14.3%) | 17 (21.8%) | 0.319 |
| Nucleic acid test | 52 | 92 | 0.106 |
| Positive | 3 (5.8%) | 1 (1.1%) | .. |
| Negative | 49 (94.2%) | 91 (98.9%) | .. |
| CT scan | .. | .. | <0.0001* |
| Recovery | 2 (3.8%) | 2 (2.2%) | .. |
| Improved | 48 (92.3%) | 90 (97.8%) | .. |
| Deterioration or new lesions | 2 (3.8%) | 0 | .. |
Data are mean (SDs), median (IQR), n (%), or n/N (%). P values were calculated by Student t test, Mann-Whitney U test, χ² test, or Fisher’s exact test, as appropriate. *χ² test comparing all subcategories.
Figure 2Prognostic factor selection using the LASSO binary logistic regression model. (A) LASSO coefficient profiles of the 45 variables. (B) Optimal parameter (lambda) selection in the LASSO model used tenfold cross-validation via minimum criteria. The partial likelihood deviance (binomial deviance) curve was plotted versus log(lambda). Dotted vertical lines were drawn at the optimal values by using the minimum criteria and the one standard error of the minimum criteria. (C) Developed mild or moderate to severe COVID−19 nomogram. (D) Calibration plot. (E) Decision curve.
Risk factors associated with mild or moderate pregressed to severe transfer from fangcang shelter hospital to the designated hospital.
| Median incubation (onset to shelter) period (≤14 VS ≥14 days) | -0.529 | 0.588 (0.158-2.076) | 0.412 |
| Fever on shelter admission (Patients — no./total no. (%)) | 2.599 | 13.459 (4.147-54.650) | <0.0001* |
| Distribution of peak temperature (≤38°C VS >38°C) | 2.421 | 11.261 (3.405-43.737) | <0.0001* |
| Sputum production | -1.127 | 0.324 (0.051-1.697) | 0.195 |
| Sore throat | 1.929 | 6.884 (0.977-77.611) | 0.081 |
| Shortness of breath | 1.706 | 5.506 (0.798-50.485) | 0.096 |
| Myalgia or arthralgia | 2.665 | 14.375 (3.223-83.279) | 0.001* |
| Poor appetite | 1.335 | 3.802 (0.785-21.792) | 0.111 |
| Headache | -2.179 | 0.113 (0.007-1.082) | 0.083 |
| Diabetes | 1.273 | 3.570 (0.298-48.145) | 0.318 |
| Distribution of CRP (<10 VS ≥10 per L) | 2.254 | 9.530 (2.145-49.634) | 0.004* |
β is the regression coefficient. OR=odds ratio. CI, confidence interval. *Statistically significant.